The treatment of acute ischemic stroke continues to advance. The mainstay of treatment
remains intravenous thrombolysis with alteplase. Recent studies demonstrated that later …

Tenecteplase is a fibrinolytic drug with higher fibrin specificity and longer half-life than the
standard stroke thrombolytic, alteplase, permitting the convenience of single bolus …

Background There is increasing interest in replacing alteplase with tenecteplase as the
preferred thrombolytic treatment for patients with acute ischaemic stroke. We aimed to …

Intravenous thrombolysis is the only approved systemic reperfusion treatment for patients
with acute ischaemic stroke. These European Stroke Organisation (ESO) guidelines provide …

Background Intravenous thrombolysis with alteplase bolus followed by infusion is a global
standard of care for patients with acute ischaemic stroke. We aimed to determine whether …

Within the last year, four randomised-controlled clinical trials (RCTs) have been published
comparing intravenous thrombolysis (IVT) with tenecteplase and alteplase in acute …

Background Tenecteplase is a modified tissue plasminogen activator with pharmacological
and practical advantages over alteplase—which is currently the only approved thrombolytic …

Background and Objectives The relevance of impaired microvascular tissue-level
reperfusion despite complete upstream macrovascular angiographic reperfusion (no-reflow) …

Background Current evidence supports the use of intravenous thrombolysis with alteplase in
patients with wake-up stroke selected with MRI or perfusion imaging and is recommended in …

Importance Tenecteplase is being evaluated as an alternative thrombolytic agent for the
treatment of acute ischemic stroke (AIS) within ongoing randomized clinical trials (RCTs). In …